Guided Therapeutics Announces Extension of Distribution Agreement for Eastern Europe and Russia
Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of a rapid and painless testing platform based on its patented biophotonic technology, today announced it has signed an extension of its distribution agreement with its Russian and Eastern European Sales and Marketing partner, Newmars Group Kft.
The contract extension commits Newmars Group to minimum orders totaling more than $20 million over the next five years, beginning next year in eight Eastern European countries and then in Russia starting in 2020. The contract extension follows a report of fresh results from Dr. Zoltan Hernadi of the University of Debrecen in Hungary that add to the positive LuViva clinical findings reported earlier this year. The new data include LuViva tests on 100 additional referral patients including 27 with cervical cancer or precancer. As in the previous set of data from the Debrecen centre, LuViva detected over 90% of the women with early cervical cancer that required treatment.
“We look forward to working with Newmars Group over the next five years to bring early detection of cervical cancer to more women in Eastern Europe and Russia,” said Gene Cartwright, CEO of Guided Therapeutics. “The new clinical results continue a run of excellent reports issued by opinion leaders around the world.”
According to the World Health Organization, cervical cancer is ranked as one of the most frequent cancers in women. Central and Eastern Europe have a population of approximately 112 million women above 15 years of age, who are at risk of developing cervical cancer. The current estimates indicate approximately 1,971 per 100,000 new cases diagnosed and 886 per 100,000 deaths annually in Central and Eastern Europe, making the control of this deadly disease a priority for those countries.
About Guided Therapeutics
Guided Therapeutics, Inc. (OTCQB: GTHP) is the maker of a rapid and painless testing platform based on its patented biophotonic technology that utilizes light for the early detection of disease at the cellular level. The Company’s first product is the LuViva® Advanced Cervical Scan, a non-invasive device used to detect cervical disease instantly and at the point of care. In a multi-center clinical trial with women at risk for cervical disease, the technology was able to detect cervical cancer up to two years earlier than conventional modalities, according to published reports. For more information, visit: www.guidedinc.com.
The Guided Therapeutics LuViva ® Advanced Cervical Scan is an investigational device and is limited by federal law to investigational use in the U.S. LuViva, the wave logo and "Early detection, better outcomes" are registered trademarks owned by Guided Therapeutics, Inc.
Forward-Looking Statements Disclaimer: A number of the matters and subject areas discussed in this news release that are not historical or current facts deal with potential future circumstances and developments. The discussion of such matters and subject areas is qualified by the inherent risks and uncertainties surrounding future expectations generally and also may materially differ from Guided Therapeutics’ actual future experience involving any of or more of such matters and subject areas. Such risks and uncertainties include those related to the early stage of commercialization of products, the uncertainty of market acceptance of products, the uncertainty of development or effectiveness of distribution channels, the intense competition in the medical device industry, the sufficiency of capital raised in prior financings and the ability to realize their expected benefits, the uncertainty of future capital to develop products or continue as a going concern, the uncertainty of regulatory approval of products, and the dependence on licensed intellectual property, as well as those that are more fully described from time to time under the heading “Risk Factors” in Guided Therapeutics’ reports filed with the SEC, including Guided Therapeutics’ Annual Report on Form 10-K for the fiscal year ended December 31, 2017 and subsequent filings.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181108005423/en/